Decentralised Trials are the Future.
COVID-19 has changed clinical trials forever. To find out how CROs have adapted to the global pandemic and whether this will have a lasting impact ...
More and more companies are striving to build diverse and inclusive teams. I wanted to speak to an expert at this, who works within the life sciences arena, to find out what they do.
There’s so much potential in analytical instrumentation. After a challenging 2020, next year presents itself as a fresh start for the market and these are the companies that you need to keep an eye on.
For this episode of CM Conversations, our Director of Operations Tom Maskill spoke with QIAGEN CEO Thierry Bernard.
In my line of work you come across new companies everyday, however, few are as forward-thinking and unique as Norman Health. I spoke to the company's founder and Managing Director, Jan-Wilem Eleveld.
For decades, we’ve been talking about how NGS will change the world. But what if NGS was only the start?
Animal feed is now responsible for up to 70% of the cost of animal production. To get this figure down and to be more environmentally friendly, the animal market has shifted to sustainable alternatives like additives and different feed sources.
Only 30% of executive positions and 18% of board seats are held by women in biotech. I spoke to industry expert, Melissa Gammell, to find out where we're going wrong, how we get more women into biotech and how we keep them there.
In this episode of CM Conversations, our lab equipment specialist Lucy Smith spoke with Melissa Gammell, Vice President of Business Development at Matphil Technologies about the challenges facing women in biotech.
Cytosurge's tiny syringes are a game changer for the single cell genomic and gene editing applications; since patenting the technology in 2009 the company has gone from strength to strength.
In this episode, our specialist in the lab equipment space, Lucy Smith, spoke with CEO of Elementar Americas Ryan Titmas. Lucy spoke to Ryan about what it takes to get to the top, as well as some of the lessons he’s learned in his career so far.
When we talk about genomics hubs, then usually we’d be talking about Oxbridge, Boston or Silicon Valley thanks to success stories like 10x Genomics, Illumina or Solexa. However, as the technology needed to conduct genomic R&D becomes more accessible
Coronavirus has provided us with a very large and extremely recent data set for research, patient populations and how different ethnic minorities are being affected versus the research. And the early indicators are that those from minority background